AKTS (Aktis Oncology) Net Margin %: -567.86% (As of Mar. 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $31.15
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology Net Margin %?

Aktis Oncology AKTS +8.54% 9 Net Margin % is -567.86% as of Mar. 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, Aktis Oncology ranks worse than 74.21% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Aktis Oncology's Net Income for the three months ended in Mar. 2026 was $-18.33 Mil. Aktis Oncology's Revenue for the three months ended in Mar. 2026 was $3.23 Mil. Therefore, Aktis Oncology's net margin for the quarter that ended in Mar. 2026 was -567.86%.

The historical rank and industry rank for Aktis Oncology's Net Margin % or its related term are showing as below:

AKTS' s Net Margin % Range Over the Past 10 Years
Min: -2957.63   Med: -1969.28   Max: -656.52
Current: -656.52

AKTS's Net Margin % is ranked worse than
74.21% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs AKTS: -656.52

Aktis Oncology  (NAS:AKTS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Aktis Oncology Net Margin % Related Terms

Aktis Oncology Net Margin % Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Net Margin % Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Margin %
0.00 0.00 -2,957.63 -980.93

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial -1,292.18 -1,035.59 0.00 -809.52 -567.86

AKTS vs OLMA, EYPT, ZBIO: Net Margin % Comparison

For the Biotechnology subindustry, Aktis Oncology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aktis Oncology Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aktis Oncology's Net Margin % distribution charts can be found below:

* The bar in red indicates where Aktis Oncology's Net Margin % falls into.


AKTS
9GF Score
Aktis Oncology Inc AKTS
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Aktis Oncology's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-63.731/6.497
=-980.93 %

Aktis Oncology's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-18.325/3.227
=-567.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -567.86% mean?
Aktis Oncology (AKTS) has a Net Margin % of -567.86% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Aktis Oncology and its competitors. According to the industry distribution chart, Aktis Oncology ranks #702 out of 946 companies in the Biotechnology industry, placing it in the top 74.2%.
Is Aktis Oncology's Net Margin % too high?
Aktis Oncology's current Net Margin % is -567.86%. Based on the distribution chart, Aktis Oncology ranks #702 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Net Margin % compare to OLMA and EYPT?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #702 out of 946 companies for Net Margin %. This places Aktis Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Net Margin % is -567.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Net Margin % of -567.86%. The current Net Margin % is -567.86%. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Net Margin % is -567.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.15
Price